Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

587 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness and tolerability of ipilimumab: experiences from 198 patients included in a named-patient program in various daily-practice settings and multiple institutions.
Eigentler TK, Schlaak M, Hassel JC, Loquai C, Stoffels I, Gutzmer R, Pätzold S, Mohr P, Keller U, Starz H, Ulrich J, Tsianakas A, Kähler K, Hauschild A, Janssen E, Schuler-Thurner B, Weide B, Garbe C. Eigentler TK, et al. Among authors: hauschild a. J Immunother. 2014 Sep;37(7):374-81. doi: 10.1097/CJI.0000000000000046. J Immunother. 2014. PMID: 25075567
In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group.
Ugurel S, Schadendorf D, Pföhler C, Neuber K, Thoelke A, Ulrich J, Hauschild A, Spieth K, Kaatz M, Rittgen W, Delorme S, Tilgen W, Reinhold U; Dermatologic Cooperative Oncology Group. Ugurel S, et al. Among authors: hauschild a. Clin Cancer Res. 2006 Sep 15;12(18):5454-63. doi: 10.1158/1078-0432.CCR-05-2763. Clin Cancer Res. 2006. PMID: 17000680 Clinical Trial.
Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting.
Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Reinhold U, Kortmann RD, Kettelhack C, Frerich B, Keilholz U, Dummer R, Sebastian G, Tilgen W, Schuler G, Mackensen A, Kaufmann R. Garbe C, et al. Among authors: hauschild a. Melanoma Res. 2008 Apr;18(2):152-60. doi: 10.1097/CMR.0b013e3282f702bf. Melanoma Res. 2008. PMID: 18337653
587 results